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Abstract. E7820 is an orally active inhibitor of α2-integrin mRNA expression, currently tested in phases I
and II. We aimed to evaluate what levels of inhibition of integrin expression are needed to achieve tumor
stasis in mice, and to compare this to the level of inhibition achieved in humans. Tumor growth inhibition
was measured in mice bearing a pancreatic KP-1 tumor, dosed at 12.5–200 mg/kg over 21 days. In the
phase I study, E7820 was administered daily for 28 days over a range of 0–200 mg, followed by a 7-day
washout period. PK-PD models were developed in NONMEM. α2-Integrin expression measured on
platelets, corresponding to tumor stasis at t=21 in 50% and 90% of the mice (Iint,50, Iint,90) were
calculated. It was evaluated if these levels of inhibition could be achieved in patients at tolerable doses.
One hundred nineteen α2-Integrin measurements and 210 tumor size measurements were available from
mice. The relationship between PK and α2-integrin expression was modeled using an indirect-effect
model, subsequently linked to an exponential tumor growth model. Iinh,50 and Iinh,90 were 14.7% (RSE
7%) and 17.9% (RSE 8%). Four hundred sixty two α2-integrin measurements were available from 29
patients. Using the schedule of 100 mg qd (MTD), α2-integrin expression was inhibited more strongly
than the Iint,50 and Iint,90 in greater than 95% and greater than 50% of patients, respectively. Moderate
inhibition of α2-integrin expression corresponded to tumor stasis in mice, and similar levels could be
reached in patients with the dose level of 100 mg qd.
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INTRODUCTION
The investigational anti-cancer drug E7820 is an orally
active angiogenesis inhibitor, and has shown anti-tumor
activity in several tumor models in mice, the effect of which
was mediated through the inhibition of expression of α2-
integrin (1,2). Integrins are receptors that mediate attachment
between cells, and between cells and the extracellular matrix
(3). They also play an important role in cell signaling. Many
types of integrins have been identiﬁed, multiple types may be
expressed on the cell surface simultaneously. Integrins are
heterodimers, consisting of α (alpha) and β (beta) subunits.
In mammals, 18 α and 8 β subunits have been characterized,
with varying functions related to cell attachment and cell
signaling. It has been shown in preclinical experiments that
suppression of integrin α2 by E7820 played a crucial role in
inhibition of endothelium tube formation (1,2). E7820 was
evaluated in a phase I dose escalation study in patients with
malignant solid tumors or lymphomas, the clinical results of
which have been reported previously (4) and for which a
population PK model was presented before (5). Since α2-
integrin is expressed both on tumor cells and on platelets, it
has been hypothesized that α2-integrin expression on platelets
may be an easily evaluable biomarker for tumor growth
inhibition in response to treatment with E7820 (1,2).
The inhibition of α2- i n t e g r i nm e a s u r e do np l a t e l e t s
provides a measure of pharmacological target modulation,
and therefore would theoretically provide a better predictor
of activity than measures of E7820 plasma exposure. α2-
Integrin is therefore currently being evaluated in phase I
studies as possible biomarker (4,6). In this article, we present
a modeling and simulation analysis that integrates data from
preclinical experiments and a phase I clinical trial to evaluate
the expected efﬁcacy of the dose levels that were studies in
phase I. Similar analyses have been presented earlier for the
development of everolimus (7) and geﬁtinib (8). The aim of
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humans which corresponded to inhibition levels associated
with tumor stasis in mice. Therefore, we ﬁrst aimed to
establish what level of α2-integrin inhibition corresponds to
tumor stasis in mice. This was done by establishing PK-PD
models for the preclinical experiments, describing the rela-
tionships between E7820 plasma exposure, the inhibition of
α2-integrin expression, and tumor growth inhibition. Subse-
quently, we investigated if the dose regimen proposed from
the phase I study based on acceptable toxicity would result in
sufﬁcient inhibition of α2-integrin expression to expect anti-
tumor activity in patients. For this, a model was constructed
describing effects of exposure to E7820 on α2-integrin
expression. This model was based on the human PK model
and measurements of α2-integrin during the phase I trial.
Finally, it was evaluated which clinical regimens were capable
of achieving inhibition of α2integrin expression in humans
similar to that which led to tumor stasis in mice. It was thus
assumed that a similar level of α2-integrin expression would
be required for tumor growth inhibition in mice and humans,
for tumors that are sensitive to angiogenesis inhibition
mediated by α2-integrin.
METHODS
Preclinical Experiments
The PK proﬁle of E7820 in female KSN Slc mice aged 6,
7, or 8 weeks was elucidated after single IV (25 mg/kg, n=3),
single oral (25, 50, and 100 mg/kg, n=4), and seven repeated
oral administrations with about 12 h intervals (50 mg/kg, n=
4). Concentrations of E7820 in plasma were obtained using a
validated liquid chromatography method with UV detection,
with precision <15% over the entire concentration range.
Mean PK parameters CL, V, and F were calculated by non-
compartmental analysis. The tumor growth experiments in
mice have been described before (1). Brieﬂy, a human
pancreatic carcinoma cell line (KP-1, 5×10
6 cells/head) was
transplanted subcutaneously into 7-week old female nude
mice. Administration of E7820 was started at doses of 12.5,
25, 50, 100, or 200 mg/kg, or vehicle, 1 week after the
transplantation. E7820 was administered orally by gavage,
twice a day for 3 weeks. PK samples were collected twice
weekly. Blood was withdrawn once a week from the eye of
anesthesized mice in PBS containing 0.004% sodium citrate
and diluted at 1:100. Diluted blood samples were directly
stained with FITC-conjugated anti-integrin α2A ba n d
expression levels on platelets were analyzed by ﬂow
cytometry. The longest diameter of the tumor and body
weight was measured twice a week by direct measurement of
the tumor diameters with calipers.
Software
The statistical data analysis and simulations were per-
formed with non-linear mixed-effects modeling using NON-
MEM, version VI, level 2.0 (Icon Development Solutions,
Ellicott City, MD, USA) with gfortran (http://gcc.gnu.org/
fortran/) as Fortran compiler, and Piraña (9) as modeling
environment. The ﬁrst-order conditional estimation method
with interaction (FOCE-I) was used throughout the model
building. Standard errors for model parameters were esti-
mated using the covariance step in NONMEM. Model
evaluation and selection was based on objective function
value (p level of 0.01, ΔOFV=6.63 was considered a
signiﬁcant improvement in ﬁt), successful convergence, good-
ness-of-ﬁt plots and visual predictive checks (10). R (version
2.9.0, http://www.cran.r-project.org) was used for the analysis
of simulated data, and the generation of plots. Modeling and
simulation were performed according to a pre-speciﬁed
analysis plan, and construction of the PK-PD model was
performed sequentially. First, the effect of E7820 plasma
concentrations was correlated with the inhibition of α2-
integrin expression. Next, a tumor growth model based on
the unperturbed tumor growth experiment was ﬁtted. The
parameter estimates for the α2-integrin model were then
ﬁxed, and the model predicted expression levels were used to
drive the different tumor growth models that were evaluated.
Integrin Expression in Mice
Longitudinal description of the α2-integrin expression
level on platelets was modeled as an indirect response model
(11) with an inhibitory effect on input rate (kin) of E7820
plasma concentration, described by a linear equation or by
the Hill equation:
dI
dt
¼ kin   1  
Emax;I   cg
p
IC
g
50;I þ c
g
p
 !
  kout   I ð1Þ
in which I describes the relative integrin expression, kin and
kout are the input and output rates of the indirect-effect
model. The plasma concentration of E7820 was deﬁned as cp,
and Emax,I,I C 50 and γ were the maximal drug effect, the
plasma concentration at half maximal effect, and the shape
exponent of the Hill equation describing the drug effect on
the α2-integrin expression rate, respectively. An inhibitory
effect of plasma exposure on kin was considered a mechanis-
tically more plausible model than a stimulatory effect on kout
as the pharmacological effect of E7820 is mediated through
the inhibition of mRNA expression. α2-Integrin expression at
baseline (I0)was estimated (12). To allow for hysteresis in
drug effects on α2-integrin, the inclusion of one or more effect
compartments was tested. It was also assessed if development
of tolerance to E7820 could be shown.
Tumor Growth in Mice
Two prerequisites for the tumor growth model were
established: the model should be able to (a) capture the
unperturbed growth, and (b) capture the inhibitory effect of
decreased α2-integrin expression on tumor growth/shrinkage
rate, over the entire dose range of E7820. Several tumor
growth models were evaluated, including exponential models,
Gompertz models (13), and a tumor growth model introduced
by Simeone et al.( 14). Linear and Emax relationships were
evaluated for their ability to correlate the effect of inhibition
of α2-integrin expression to one of the relevant growth rate
parameters in the tumor growth models. For both the model
for α2-integrin and the tumor growth model, it was evaluated
if the available data supported the estimation of between
231 Dose Evaluation E7820 Using Biomarkersubject variability (BSV) of the parameters. For both models,
exponential residual error model were used.
Calculation of Efficacious α2-Integrin Inhibition
Using stochastic simulations from the preclinical PK-PD
model, it was investigated what level of inhibition of
expression of α2-integrin correlated with tumor stasis.
Achieving tumor stasis at t=21 days (end of treatment period
in preclinical experiments) in 50% or 90% of mice were
deﬁned as targets. The inhibition of α2-integrin expression
(Iint,av) at steady state was chosen as the measure of inhibition
of α2-integrin expression required to achieve these goals. The
simulations were performed for dose levels varying from 50 to
200 mg/kg with 20-mg/kg intervals, and each simulations was
performed for 500 mice. In each simulation, the percentage of
mice having tumor sizes less than or equal to their baseline
tumor sizes was recorded, along with the Iinh,av. From the
results of the simulations, relationships between dose level,
α2-integrin inhibition and tumor growth inhibition at t=21
were plotted, and the Iint,av values at which 50% and 90% of
mice achieved tumor stasis were calculated (Iinh,90 and Iinh,50).
To account for uncertainty in model parameter estimates, and
to calculate relative standard errors (RSE) for these targets,
these simulations were repeated 250 times with parameters
sampled from the variance–covariance matrix obtained for
the model.
Clinical Trial Data
E7820 was administered to patients daily for 28 days,
followed by a washout period of 7 days prior to starting
subsequent cycles. Blood samples were collected from 1 up to
9 treatment cycles. Bioanalysis of PK was performed using
the same method as used for the preclinical samples. Blood
samples for α2-integrin expression were determined from
blood collected at predose, and at 6 h post-drug adminis-
tration on day 1, predose on day 28 of cycle 1 and at 24 h
post-drug administration. Beyond cycle 1 and for each
subsequent cycle, blood was collected on day 28 predose.
Diluted blood samples were directly stained with FITC-
conjugated anti-integrin α2 Ab and expression levels on
platelets were analyzed by ﬂow cytometry, and expressed in
molecules of equivalent soluble ﬂuorochrome.
Modeling of Clinical Data
Previously, a population PK model was constructed from
data from the phase I trial (Table I)( 5). This model was used
here as well, however, to avoid difﬁculties arising from
incorporation of multiple dosing in the turnover absorption
model, the absorption model was simpliﬁed to a ﬁrst-order
absorption model. The empirical Bayesian estimates (EBEs)
for oral clearance (CL/F) and volume of distribution (V/F),
and typical parameter values for ka obtained from this PK
model and the observed data were used to drive the PD
model for α2-integrin expression. Within-subject variability in
PK parameters was disregarded in the PD analysis. For the
clinical data, a similar indirect-effect model for the inhibition
of α2-integrin expression was evaluated as was used for the
preclinical data. It was evaluated if the available data
supported the estimation of BSV on the PD parameters.
Dosing regimens of 50, 70, 100, and 200 mg qd were then
simulated using the developed model to investigate the
expected inhibition of α2-integrin expression during continu-
ous treatment at these levels. These simulations were
performed in 1,000 patients, to account for inter individual
variability in response to E7820. The relative α2-integrin
inhibition at steady state was calculated (two cycles), which
was compared to the Iinh,av that was required for tumor stasis
calculated from the preclinical data.
RESULTS
PK in Mice
In the PK experiments in mice, elimination half-life was
0.63 h and a low plasma clearance (CL=7.85 mL min
−1 kg
−1)
and low volume of distribution (V=0.684 L/kg) after IV
dosing of E7820 were observed. The observed PK proﬁles
after IV administration were monophasic, and a linear
increase of AUC was observed from 25 to 100 mg/kg after a
single oral dose. As the absorption was rapid with a tmax at
∼1 h, an absorption rate (ka) of 3 h
−1 was used throughout.
Plasma protein binding of E7820 was concentration
independent from 5 to 100 mg/L, and was 89% (range 88.0–
90.2%). Mean bioavailability after oral administration of
25 mg/kg was 61.3%. E7820 showed anti-tumor activity at
doses of 50, 100, and 200 mg/kg in the tumor growth and α2-
integrin expression experiments.
Integrin Inhibition in Mice
The exposure–response relationship between E7820
plasma concentration and the inhibition of input rate of the
turnover model was signiﬁcantly better described using an
Emax-equation than when using a linear relationship. An Emax
value of 1.1 (RSE 36%) was estimated, but was not
signiﬁcantly different from 1. Likely, due to the fact that α2-
integrin expression was inhibited maximally by only 30%, a
sigmoidal Emax model could not be estimated. Therefore, the
Table I. Characteristics of Clinical Phase I Study (4)
Value (range)
Total number of patients 36
Dose level 10 mg 3
20 mg 4
40 mg 3
70 mg 3
100 mg 17
200 mg 6
Sex Male 20
Female 16
Race Caucasian 31
Black 1
Hispanic 4
Weight (kg) 70.9 (43.2–113.6)
Height (cm) 167.3 (150.5–182.9)
BSA (m
2) 1.805 (1.375–2.402)
Age (years) 64.8 (40.0–82.0)
Continuous variables given as mean (range) and categorical data as counts
232 Keizer et al.shape parameter γ in the Hill equation was ﬁxed to 1,
reducing the exposure–response relationship to a non-
sigmoid Emax model. The inclusion of delay in the effects of
drug exposure on α2-integrin expression did not signiﬁcantly
improve model ﬁt, nor did the inclusion of a term describing
resistance to the inhibition of α2-integrin expression by
E7820. Figure 1 shows a visual predictive check of the model
describing α2-integrin expression, which indicated adequate
model ﬁt.
Tumor Growth in Mice
Although all evaluated tumor growth models were able
to describe unperturbed growth, only when an exponential
model was used could the effects of integrin inhibition be
captured adequately over the entire dose range studied in the
preclinical experiments. In the exponential model, it was
however necessary to include an adjustment for the observed
initial slow tumor growth, since almost no tumor growth or
even tumor shrinkage in some mice (receiving only vehicle)
w a so b s e r v e di nt h eﬁrst week. This was captured by
including a mono-exponential term describing an initially
complete and gradually decreasing resistance to tumor
growth, on top of the basic exponential tumor growth
differential equation:
dT
dt
¼ a   1   e b t   
  T ð2Þ
with T describing the tumor size in mm, α describing the
tumor growth rate, β being the rate of decline of initial
resistance to maximal unperturbed tumor growth, and t being
the time in days after start of treatment. The inhibitory effect
of decreased α2-integrin expression on tumor growth was
incorporated as a sigmoidal Emax function, implemented
relative to current tumor size:
dT
dt
¼ a   1   e b t   
  T  
Emax;T   I
g
inh;t
II
g
50 þ I
g
inh;t
  T ð3Þ
Emax,T,I I 50 and γ are the maximal effect of inhibition of
α2-integrin expression, the plasma concentration at half
maximal effect, and the Hill coefﬁcient, respectively. The Hill
coefﬁcient could not be estimated, and was therefore ﬁxed at
5 to allow sigmoidicity in the relationship. This provided
signiﬁcantly better ﬁt than using the non-sigmoidal form. The
inclusion of a delay between the effect of α2-integrin
inhibition on tumor growth did not result in a signiﬁcantly
better model ﬁt. All parameters could be estimated with
reasonable precision, except the parameters describing
unperturbed growth. The high uncertainty (>100%) in
estimation of these parameters could be explained by the
fact that these estimates were obtained by ﬁtting only the
tumor growth data from the ﬁve mice that received vehicle
and no drug. A visual predictive check, shown in Fig. 2,
however showed that the model described the observed data
accurately for these mice, and also for the other mice, when
the effects of decreased α2-integrin expression were incorpo-
rated in the model.
A schematic representation of the structural model
describing the tumor growth inhibition and α2-integrin
expression is shown in Fig. 3, and parameter estimates for
the PK-PD model are presented in Tables II, III, and IV. The
tumor growth model was able to describe the tumor growth in
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Fig. 1. α2-Integrin expression proﬁles in mice with implanted KP-1 tumors at different dose levels of
E7820. The thin solid lines indicate observed growth curves, the black solid line indicates the model
predicted growth curve, and the gray areas indicate the 80% conﬁdence interval of the model predictions
233 Dose Evaluation E7820 Using Biomarkerthe mice with adequate precision for all dose levels, as can be
seen in the plots in Fig. 2 which show both the observed
tumor growth curves and the 80% of model predictions (i.e.
between-mice variation in tumor size, and inhibition of tumor
growth rates). The plots reveal that tumor growth was
considerably inhibited from doses of 50 mg/kg upward, but
that tumor stasis (relative to baseline) at t=21 was only
achieved at doses of 100 and 200 mg/kg. In Fig. 4, the
relationships between dose level, inhibition of α2-integrin
expression, and tumor growth inhibition are plotted, which
were calculated from simulated tumor growth experiments.
The inhibition of α2-integrin expression at steady state that is
required for tumor stasis in 50% and 90% of mice (Iinh,50 and
Iinh,90) were calculated to be 14.7% (RSE 7%)and 17.9%
(RSE 8%), respectively.
Analysis of Clinical Trial Data
In total, 462 α2-integrin level measurements at 209
unique timepoints were available from 29 patients with
solid tumors or lymphoma. The same turnover model that
was used in the preclinical experiments was used to
describe the α2-integrin proﬁles observed in the clinical
trial. It was observed that the estimate for the turnover
rate parameter (kout) in the clinical model (0.099) was
fairly similar to the estimate for the preclinical model
(0.143), suggesting that rates of integrin inhibition are
comparable, and only slightly faster in the preclinical
setting. The estimate for IC50 value obtained for the
clinical model was about fourfold higher than obtained
for the preclinical model. Although BSV in baseline levels
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Fig. 2. Tumor growth curves in mice with implanted KP-1 tumors at different dose levels of E7820. The
thin solid lines indicate observed growth curves, the black solid indicates model predicted growth curve,
and the gray area indicate the 80% conﬁdence interval of the model predictions
Fig. 3. Structure of the preclinical PK-PD-tumor growth model. The
clinical model had the same structure, but did not incorporate a
sub-model for tumor size
234 Keizer et al.and drug sensitivity were high, signiﬁcant effects of plasma
drug exposure on the inhibition of α2-integrin expression
were observed, and an Emax model best described this
relationship. The data allowed the estimation of BSV in
baseline α2-integrin expression levels and drug sensitivity
(IC50). A delay in drug effect did not improve the model,
nor did a model that incorporated development of toler-
ance to E7820. Figure 5 shows a visual predictive check of
the model and the data, in which dose levels of less than or
equal to 50 mg qd, and dose levels of greater than or equal
to 70 mg were grouped. This ﬁgure shows that the
observed proﬁles correspond to the median model pre-
dicted proﬁles, and that most of the observed proﬁles are
contained within the 90% conﬁdence interval of the model
predictions.
Simulations of Clinical Regimens
In Fig. 6, the results of simulations for the four highest
dose levels that were studied in the phase I trial are plotted,
along with the steady state level of α2-integrin expression
inhibition corresponding to tumor stasis in 50% and 90% of
mice. In Table V, the average inhibition of α2-integrin
expression (Iint,av) after one cycle of E7820 of 28 days in
patients is shown. These results demonstrate that a regimen
of 50 mg qd is expected to result in less than 50% of patients
achieving the deﬁned target of both Iinh,50 and Iinh,90.A t
continuous dosing at 70 mg qd, inhibition of α2-integrin
expression is expected to achieve the Iinh,50 target in >50% of
patients, but the median expected integrin level is slightly
lower than the Iinh,90. At doses of 100 mg qd, median
inhibition is higher than both targets, although the 95%
conﬁdence interval was not entirely higher than the Iinh,90
target. Only at the highest evaluated but toxic dose of 200 mg
qd are 95% of patients expected to achieve inhibition of
expression higher than both targets. This dose level has
however been shown to induce non-tolerable hematological
toxicity (15).
DISCUSSION
We have presented here a ﬁrst population PK-PD
analysis of preclinical and clinical data of the α2-integrin
inhibitor E7820, and evaluated relationships between expo-
sure to E7820, α2-integrin expression and tumor growth.
Integrin inhibitors have been introduced recently as potential
new treatment modalities in anti-cancer treatment that inhibit
tumor growth by inhibiting angiogenesis. Integrins are
heterodimer transmembrane receptors that are essential
factors in angiogenesis as they mediate endothelial cell
migration, proliferation and survival (16). Preclinical studies
have shown that the inhibition of integrins, either by
Table II. PK Model Parameters Based on the Preclinical and Clinical Studies
Parameter Preclinical (mice) Clinical
PK Estimates (IB) Estimates(5) RSE
CL
a Clearance 0.471 L h
−1 kg
−1 6.24 L h
−1 5%
V
a Volume of distribution 0.684 L kg
−1 66.0 L 8%
F Oral bioavailability 69.3 % –
ka Absorption rate 3
b h
−1 0.889 h
−1 7%
ωCL BSV in clearance (CV) – 51 % 12%
ωV BSV in volume of distribution (CV) – 48 % 17%
ρCL∼V Correlation CL∼V (CV) – 62 % 12%
aClinical estimates for clearance and volume of distribution are given as CL/F and V/F
bAbsorption rate unknown, but assumed rapid (3 h
−1) in preclinical experiments (tmax was observed at ∼1h )
BSV between subject variation, RSE Relative standard error (%), CV coefﬁcient of variation (%)
Table III. PD Model Parameters for Integrin Model Based on the Preclinical and Clinical Studies
Parameter Preclinical (mice) Clinical
PD: α2-integrin model Estimates RSE Estimates RSE
Ibase Baseline integrin level 22.5 % (1%) 8,350 MESF 1%
Kin Input rate turnover model 3.21 %day
−1 (19%) 825.6 MESF day
−1 14%
Kout
b Output rate turnover model 0.143 day
−1 0.099 day
−1
Emax,C Maximal effect of E7820
exposure on integrin inhibition
1
a 1
a
IC50 Concentration at 50% of maximal
effect
656 ng ml
−1 (18%) 2,840 ng ml
−1 32%
ωI,base BSV in integrin baseline 31 % (40%) 40.0 % 19%
ωeff BSV in sensitivity to E7820 ––110 % 32%
σexp Exponential residual error (CV) 6.7 % (8%) 11.5 % 23%
MESF molecules of equivalent soluble ﬂuorochrome
aFixed
bNot estimated, but calculated as Ibase/Kin
235 Dose Evaluation E7820 Using Biomarkermonoclonal antibodies, peptide drugs, or small molecules can
result in tumor remission (16,17). Currently, integrin inhib-
itors are investigational drugs and are in clinical and
preclinical testing as single agents or in combination with
other anti-cancer agents.
From experiments in mice, we were able to model with
good accuracy the effects of drug exposure on levels of α2-
integrin inhibition and tumor growth suppression in mice.
The inhibition of α2-integrin expression levels was described
by an indirect-effect model, which is the most widely used
pharmacodynamic model for describing physiological pro-
cesses. The model was able to describe the decrease in α2-
integrin expression over time in response to treatment with
E7820 and account for the between-mice variation in drug
response. A simple exponential tumor growth model was then
used to describe tumor growth proﬁles in mice; with the
predicted α2-integrin expression levels driving growth inhib-
ition A Gompertz model (13) provided worse ﬁt than the
empirical exponential model. Although tumor growth models
have been presented in literature that is somewhat more
physiologically based than the exponential model (14,18), this
model could also not describe our tumor growth better than
the exponential model. More importantly, as the aim of this
study was not to scale or extrapolate the tumor growth model
to other species or other drugs, but primarily in accurately
describing the relationship between α2-integrin expression
and tumor growth, the exponential model was deemed most
adequate. It should be stressed that the term (1   e b t )
included in the model does not describe drug resistance but
rather initial slow tumor to growth, and that the rate
parameter β was estimated solely based on the unperturbed
growth curves. The initial slow growth rate may be due to the
transplanted tumor not being fully embedded yet in the
tumor environment, and thus not fully able to receive
nutrients and oxygen needed for growth. Although admin-
istration of E7820 started 7 days after transplantation of the
tumor, this period may thus not be long enough to achieve the
full potential tumor growth rate. It was noticed that t1/2 was
much lower in mice than in humans (1.01 h versus 7.33 h).
Additionally, relatively higher doses were administered to
Table IV. PD Model Parameters for the Tumor Growth Model Based on the Preclinical and Clinical Studies
Parameter Preclinical (mice)
PD: Tumor growth model Estimates RSE
Tbase Baseline tumor size 5.14 mm 1%
α Maximal exponential growth rate 0.0903 day
−1 103%
β Rate of initial resistance to tumor growth 0.0391 day
−1 130%
Emax,I Maximal effect of integrin inhibition on tumor growth 0.0472 day
−1 5%
II50 Relative inhibition of integrin expression at 50% of maximal effect 11.4 % 6%
ωT,base BSV in baseline tumor size 6 % 13%
ωII50 BSV in sensitivity to integrin expression inhibition 20 % 50%
σexp Exponential residual error (CV) 6 % 6%
60 80 100 120
−
3
5
−
3
0
−
2
5
−
2
0
−
1
5
−
1
0
−
5
0
Dose level (mg/kg)
I
n
t
e
g
r
i
n
 
e
x
p
r
e
s
i
o
n
 
a
t
 
s
.
s
.
 
(
%
)
60 80 100 120
Dose level (mg/kg)
T
u
m
o
r
 
s
i
z
e
 
(
%
)
−20 −15 −10 −5 0
−
2
0
0
2
0
4
0
6
0
8
0
−
2
0
0
2
0
4
0
6
0
8
0
Integrin expression at s.s.(%)
T
u
m
o
r
 
s
i
z
e
 
(
%
)
a bc
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236 Keizer et al.mice than humans (maximum doses 200 mg/kg in mice vs
200 mg in humans). Therefore, much higher Cmax concen-
trations were reached in mice, although E7820 was cleared
faster. This may be important: apparently higher concentra-
tions were required in mice compared to humans to elicit a
response in integrin expression. However, inhibition of
integrin expression in patients was already observed at the
MTD of 100 mg, and therefore higher doses were not
required to achieve pharmacological activity.
Using simulations from the combined preclinical model
for E7820 exposure, α2-integrin and tumor growth, targets
levels of α2-integrin inhibition that are expected to lead to
tumor stasis in 50% and 90% of mice, Iinh,50 and Iinh,90, were
estimated. The PK-PD model describing the relationship
between E7820 exposure and α2-integrin expression in
patients was then used to evaluate if these targets could be
met with the regimens that were investigated in the clinical
trial. This analysis showed that only at the highest toxic dose
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Fig. 5. a–b. Visual predictive check of the PK-PD model for α2-integrin expression on platelets in patients,
for dose levels of ≤50 mg qd (a), and ≥70 mg qd (b). The thin solid lines show the individual observed
integrin expression levels. Thick solid lines indicate model predicted median integrin expression over time,
while the gray area indicates the 90% interval of the predicted between patient variation
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237 Dose Evaluation E7820 Using Biomarkerof 200 mg qd, both targets were met in more than 95% of
patients. However, a continuous daily dose of 100 mg would
achieve the lower target (Iinh,50)i nm o r et h a n9 5 %o f
patients, and more than 50% of patients would achieve the
deﬁned high target. These results suggest that, for tumors that
are susceptible to reduced α2-integrin expression, the pro-
posed dose of 100 mg qd is likely to achieve sufﬁcient
inhibition of α2-integrin expression to achieve tumor growth
inhibition. Based on this analysis, doses of 50 mg qd or lower
are however unlikely to achieve efﬁcacy.
This analysis provides evidence to support the notion
that relative α2-integrin expression as measured on plate-
lets may serve as a clinical biomarker for treatment
efﬁcacy. Considerable variation in baseline α2-integrin
expression was observed between patients, thereby dimin-
ishing the predictive performance of absolute expression
levels. However, limited experiments in healthy volunteers
have shown that the expression is constant over time (1)
and analysis of the data from the clinical study shows that
expression remained constant in patients receiving low
doses of E7820. A signiﬁcant effect of drug exposure on
the inhibition of α2-integrin expression was found. This
suggests that the level of α2-integrin expression as meas-
ured on platelets relative to the baseline level could serve
as a biomarker to assess target modulation in response to
treatment with E7820. Since the α2-integrin inhibition
targets obtained from the preclinical experiments were
low (<20%), this suggest that even moderate inhibition of
α2-integrin expression on platelets is correlated with tumor
growth inhibition.
In the development of new drugs, results from preclinical
efﬁcacy and toxicity experiments are generally only used to
serve as input for the early clinical stage, i.e., to provide a safe
starting dose. Once in the clinical stage, results from
preclinical efﬁcacy experiments, i.e., tumor growth experi-
ments, are often not taken into account. In this analysis, in
contrast, we present an integrated model-based analysis of all
data currently available on E7820: data obtained from
preclinical experiments were projected onto data obtained
from a clinical trial. As data from the preclinical stage may
hold valuable information on the in vivo drug response,
especially when combined with data on a suitable pharmaco-
dynamic biomarker, such an analysis may allow an early
assessment of efﬁcacy.
It is currently unknown how different tumor types will
respond to E7820 exposure, and to the inhibition of integrin
expression. It is also not clear yet which tumor types respond
best to this compound. Likely, not all tumor types will be
sensitive to the inhibition of integrin, and therefore the value
of integrin expression as a biomarker must be assessed in
more detail in subsequent studies. The preclinical PD model
was built using data obtained using a pancreatic cell line. If
more preclinical data would become available, the model
could be updated with other cell-lines as well, to provide a
more robust model, or a model tailored to speciﬁc tumor
types. Another important consideration with this analysis is
the role that integrins play in mouse compared to humans. In
the preclinical experiments, integrins on platelets were of
mouse origin, while those on tumor were of human origin.
How this impacts the results is unclear, and calls for caution in
interpretation of the results. Another consideration is that
tumor growth rates and integrin turnover rates may differ
between mice and humans. Additionally, as in patients, larger,
necrotic, and more variably sized tumors are encountered and
blood supply to tumors is likely to differ between the two
species. Further clinical investigation is therefore needed to
conﬁrm the results of this analysis. Additional biomarker and
tumor growth collected from a homogeneous group of
patients will allow reﬁnement of the current model, and will
establish validity of α2-integrin as a biomarker for tumor
growth inhibition. However, in our opinion, the analysis
presented here is the most informative analysis that is
possible at the current stage of development of this drug, as
it not only takes into account the clinical results but also
results from the preclinical phase.
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